Literature DB >> 1897330

Spontaneous anovulation causing disappearance of cyclical symptoms in women with the premenstrual syndrome.

S Hammarbäck1, U B Ekholm, T Bäckström.   

Abstract

In the premenstrual syndrome the negative symptoms appear during the luteal phase of the menstrual cycle. Ovulation and the formation of a corpus luteum seem to be of great importance in precipitating the syndrome. In a large group of women with premenstrual syndrome investigated daily with symptom ratings and weekly plasma estradiol and progesterone assays, 8 were found to have one ovulatory and one spontaneously occurring anovulatory menstrual cycle. In both these cycles, the post- and premenstrual phases were compared by testing for recurrence of symptoms. All patients showed a highly significant cyclical worsening of negative premenstrual symptoms during the ovulatory cycles, whereas in the anovulatory cycles the cyclical symptoms disappeared, resulting in relief of the premenstrual syndrome. These results support earlier hypotheses, suggesting that the premenstrual syndrome appears as a result of provoking factors produced by the corpus luteum. This view is in line with earlier therapeutic findings showing that induced anovulation can relieve the premenstrual syndrome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1897330     DOI: 10.1530/acta.0.1250132

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  20 in total

Review 1.  The pathophysiologic background for current treatments of premenstrual syndromes.

Authors:  Uriel Halbreich
Journal:  Curr Psychiatry Rep       Date:  2002-12       Impact factor: 5.285

2.  Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial.

Authors:  Tory A Eisenlohr-Moul; Susan S Girdler; Jacqueline L Johnson; Peter J Schmidt; David R Rubinow
Journal:  Depress Anxiety       Date:  2017-07-17       Impact factor: 6.505

Review 3.  Action by and sensitivity to neuroactive steroids in menstrual cycle related CNS disorders.

Authors:  Anna-Carin N-Wihlbäck; Inger Sundström-Poromaa; Torbjörn Bäckström
Journal:  Psychopharmacology (Berl)       Date:  2005-12-15       Impact factor: 4.530

Review 4.  Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?

Authors:  Uriel Halbreich; P M Shaughn O'Brien; Elias Eriksson; Torbjörn Bäckström; Kimberly A Yonkers; Ellen W Freeman
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 5.  GABAA Receptor-Modulating Steroids in Relation to Women's Behavioral Health.

Authors:  Torbjörn Bäckström; Marie Bixo; Jessica Strömberg
Journal:  Curr Psychiatry Rep       Date:  2015-11       Impact factor: 5.285

6.  The effect of serotonin 1A receptor polymorphism on the cognitive function of premenstrual dysphoric disorder.

Authors:  Ju-Yu Yen; Hung-Pin Tu; Cheng-Sheng Chen; Cheng-Fang Yen; Cheng-Yu Long; Chih-Hung Ko
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-10-26       Impact factor: 5.270

Review 7.  Menstrual psychosis: a bipolar disorder with a link to the hypothalamus.

Authors:  Ian F Brockington
Journal:  Curr Psychiatry Rep       Date:  2011-06       Impact factor: 5.285

Review 8.  The role of sex steroids in catamenial epilepsy and premenstrual dysphoric disorder: implications for diagnosis and treatment.

Authors:  Constance Guille; Susan Spencer; Idil Cavus; C Neill Epperson
Journal:  Epilepsy Behav       Date:  2008-03-17       Impact factor: 2.937

Review 9.  Neurosteroids in the context of stress: implications for depressive disorders.

Authors:  Susan S Girdler; Rebecca Klatzkin
Journal:  Pharmacol Ther       Date:  2007-05-24       Impact factor: 12.310

Review 10.  Update on research and treatment of premenstrual dysphoric disorder.

Authors:  Joanne Cunningham; Kimberly Ann Yonkers; Shaughn O'Brien; Elias Eriksson
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.